Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TJ101 |
| Synonyms | |
| Therapy Description |
TJ101 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and CD276 (B7-H3) linked to a camptothecin derivative, which potentially induces cytotoxicity in tumor cells expressing EGFR and CD276 (B7-H3) and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 2955). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TJ101 | TJ-101|TJ 101 | CD276 Antibody 22 EGFR Antibody 74 | TJ101 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and CD276 (B7-H3) linked to a camptothecin derivative, which potentially induces cytotoxicity in tumor cells expressing EGFR and CD276 (B7-H3) and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 2955). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07181473 | Phase I | TJ101 | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |